Pacira BioSciences Welcomes Shawn Cross as CFO to Boost Growth
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Pacira BioSciences, Inc. (Nasdaq: PCRX), renowned for its pioneering non-opioid pain treatments, is excited to announce the appointment of Shawn Cross as its new Chief Financial Officer. With a wealth of experience, Mr. Cross is set to enhance the company’s financial operations and strategic growth initiatives.
Shawn Cross: A Leader with Vision
In his new role, Shawn Cross will take charge of overseeing all financial aspects of Pacira BioSciences. His track record is impressive, showcasing over 25 years of experience as a biotechnology executive, investment banker, and board member. Frank D. Lee, CEO of Pacira, expressed his enthusiasm: “We are delighted to welcome Shawn. His leadership and guidance are pivotal as we pursue long-term growth while ensuring efficient resource allocation.”
Cross's Strong Background in Biotech Finance
Prior to joining Pacira, Mr. Cross served as the Chief Financial Officer at Applied Molecular Transport, Inc. Here, he was instrumental in leading the company through its initial public offering (IPO). His leadership eventually led him to roles as President and Chief Operating Officer, and he even took the helm as CEO during AMT’s merger with Cyclo Therapeutics, Inc. His extensive experience within the biotechnology field ensures that he brings a wealth of knowledge to Pacira.
Innovating Non-Opioid Pain Therapies
Pacira is dedicated to revolutionizing pain management with innovative, non-opioid therapies. Under the guidance of leaders like Shawn, the company is poised to continue its success with its commercial-stage products, including EXPAREL® and ZILRETTA®. These treatments are designed to provide effective pain relief alternatives, significantly impacting the lives of patients suffering from pain.
Financial Strength and Growth Prospects
Shawn Cross commented on the company’s financial stability, noting, “Pacira is on strong financial footing with a business generating robust cash flows from its market-leading products.” His insight into financial operations will be crucial as the company navigates its next phase of growth, building on its successes and exploring new opportunities.
Stock Awards and Incentives
To kickstart his role, the Compensation Committee of Pacira's Board has granted inducement awards to Mr. Cross, which includes stock options and restricted stock units. These awards aim to align his interests with the company’s long-term success and to motivate his contributions toward achieving financial and operational goals.
About Pacira BioSciences
Pacira BioSciences is committed to delivering cutting-edge, non-opioid pain therapies that transform patient care. Their flagship products—EXPAREL®, ZILRETTA®, and ioveraº®—are crafted to address various forms of pain, from postsurgical recovery to chronic osteoarthritis treatment. Additionally, the company is developingPCRX-201, a groundbreaking local gene therapy with the potential to alter the landscape of pain management.
Frequently Asked Questions
1. Who is the new Chief Financial Officer of Pacira BioSciences?
Shawn Cross has been appointed as the new Chief Financial Officer of Pacira BioSciences.
2. What experience does Shawn Cross bring to Pacira?
Shawn Cross brings over 25 years of experience in the biotechnology industry, holding various leadership roles in finance and operations.
3. What are the main products offered by Pacira BioSciences?
Pacira offers innovative non-opioid pain management solutions, including EXPAREL®, ZILRETTA®, and ioveraº®.
4. What financial initiatives are in place for Shawn Cross?
Shawn Cross has received inducement awards, including stock options and restricted stock units, to align his performance with Pacira's growth.
5. How does Pacira intend to innovate in the healthcare sector?
Pacira is committed to expanding its portfolio with the development of new therapies, like PCRX-201, aiming to enhance patient care while addressing pain without opioids.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Vicor's Earnings Forecast: Anticipations and Market Trends Ahead
- Exploring Enova International's Upcoming Earnings Forecast
- Stride Inc: Anticipating Earnings and Future Growth Prospects
- Insights into Denny's Upcoming Earnings Announcement
- Controladora Vuela Earnings Preview: What Investors Expect
- Investors Anticipate PennyMac Mortgage's Upcoming Earnings Report
- TruBridge Welcomes Amy O'Keefe to Board of Directors Team
- BHP Faces $47 Billion Lawsuit Over Mariana Dam Disaster
- Investor Optimism Growing in U.S. Fixed Income Market
- Embassy Bank Named Best in Readers' Choice with Market Growth
Recent Articles
- Pyxis Tankers Set to Showcase Innovations at ThinkEquity Conference
- Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study
- Cyabra CEO Set to Share Insights at Major Conference Event
- Waltz Health and Noom Join Forces for Innovative Weight Loss Solutions
- 5E Advanced Materials Sees Operational Success and Tax Benefits
- Pyxis Tankers Set for Engaging Participation at Conference
- CACI Secures $805 Million Contract for Naval Support Services
- Boeing's New Labor Deal Signals Hope for Stability
- Pacira BioSciences Welcomes Shawn Cross as New CFO
- Stingray Launches Innovative Video Channels for BMW Drivers
- Transformative AI Credit Underwriting at Sidney Federal Credit Union
- Ekso Bionics Prepares for Q3 2024 Financial Results Release
- o9's Groundbreaking Catena-X Certification Revolutionizes Auto Data
- Windtree Therapeutics to Showcase Innovations at a Major Event
- Protara Therapeutics Advances IV Choline Chloride for Patients
- Reynolds and Reynolds Deepens Payments Partnership with Worldpay
- Immunohistochemistry Market Expected to Reach USD 5.5 Billion
- Cumulus Media Sets Date for Q3 2024 Results Conference Call
- Kantata Honors Innovative Leaders with 2024 Catalyst Awards
- Revolutionizing Metal Extraction with Bio-Leaching at Ferguson Lake
- Mainz Biomed's 2024 Financial Performance and Growth Strategy
- NCR Atleos Partners with Tompkins to Elevate ATM Services
- Leidos Secures Major Contract for Army Network Modernization
- Transforming Wealth Management: Vise and NewEdge Partnership
- IBM's Innovative Granite 3.0: Redefining AI for Enterprises
- Cumulus Media Plans Key Conference Call for Q3 Insights
- Hazeltree Advances zConnect for Enhanced Bank Connectivity
- Discover the High-Performance Features of PIC64HX Microprocessors
- Key Financial Insights and Future Plans for Mainz Biomed
- Exciting Anticipation for SAAS NORTH 9th Annual Conference
- Ladybug Resource Group: A Nutraceutical Revolution Ahead
- Daré Bioscience Secures $15 Million Investment for Innovation
- Dynex Capital: Insights on Q3 2024 Financial Results
- Daré Bioscience Engages Lincoln Park for $15 Million Investment
- HemoSonics Secures NIH Grant to Enhance Maternal Health Solutions
- Timex Celebrates 170 Years of Innovation with Special Watch
- Bitcoin's Upward Momentum: A Promising Future Ahead
- Discover Halia Therapeutics' Innovations at Upcoming Event
- Orgenesis Launches Trading on OTCQX Following Nasdaq Delisting
- Velocity Capital Management Welcomes Texas PSF as Partner
- Understanding California's Squatter Laws and Their Impact
- CRH Ventures Launches Accelerator for Sustainable Building Startups
- Tecsys Introduces Cutting-Edge Solutions to Boost Supply Chains
- Empowering Parents for Safe Teen Driving: Essential Tips
- ECI Group Secures Major Investment for Strategic Expansion
- Dynex Capital, Inc. Announces Dividend for Shareholders
- Thompson Thrift Celebrates New Apartment Community Opening
- Driving Safety Insights: How Apps Are Supporting Teens
- Leidos Secures Major Contract for Army's Network Modernization
- LoanCare's Innovative Digital Recapture Fuels Growth for Lenders